DOMUNDI SAS

About DOMUNDI SAS

DOMUNDI SAS — often referenced in ABIONYX Pharma’s corporate documents as Domundi SC, controlled by Emmanuel Huynh — plays the role of a reference shareholder and a meaningful governance stakeholder within the listed biotech company. In ABIONYX’s official materials, Domundi is identified as having taken part in key financing transactions, including a capital increase that resulted in a significant equity stake in the company. The 2019 board report submitted to the general meeting states that Domundi, controlled by Mr. Huynh, subscribed to 2,218,750 shares, representing 10.11% of the company’s share capital, and that Mr. Huynh was also the manager of Domundi SC. The profile associated with DOMUNDI is best understood through Emmanuel Huynh’s background in listed-company strategy, investor relations, and corporate finance. Before becoming more directly involved in ABIONYX’s governance, he built experience supporting publicly traded companies, with a strong focus on financing, financial communication, and shareholder value creation. This skill set is especially relevant in biotech, where progress depends on demanding scientific, regulatory, and capital-markets milestones. At ABIONYX Pharma, Domundi has been linked to strategic phases of capital strengthening and long-term support for the business. The company has repeatedly stated that its reference shareholders, including Domundi, did not sell their holdings in recent financing steps, which signals a commitment to long-term shareholding stability. ABIONYX’s financial communications highlight its development priorities in sepsis, renal indications, and ophthalmology, as well as its ongoing efforts to secure industrial partners and fund clinical advancement. Domundi fits into that framework as a stable shareholder supporting the company’s strategic path. In summary, DOMUNDI is a shareholder and governance vehicle closely tied to Emmanuel Huynh, with a strong orientation toward listed companies and, in particular, ABIONYX Pharma. Its relevance lies in its ability to support growth transactions, structure financing initiatives, and accompany value creation in a French biotech company with significant development ambitions.